Detailed price information for Takeda Pharmaceutical Ltd ADR (TAK-N) from The Globe and Mail including charting and trades.

PepGen shifts focus to PGN-EDODM1 for Myotonic Dystrophy Type 1 after discontinuing PGN-EDO51 for Duchenne Muscular Dystrophy ...

Baxter updated its full-year 2025 guidance, expecting total sales growth of 4% to 5% on a reported basis, incorporating approximately $320 million of anticipated MSA revenues from Vantive and a 50 ...

The Tennessee Titans have reached the midpoint of a miserable, not good and just plain ugly season with a chance to rest.

Value-based oncology care requires balancing rapid innovation with operational sustainability, equitable access, and ...

Let’s dig into the relative performance of Neogen (NASDAQ:NEOG) and its peers as we unravel the now-completed Q3 medical ...

Looking back on medical devices & supplies - diversified stocks’ Q3 earnings, we examine this quarter’s best and worst ...

OVBC] (the "Company") reported consolidated net income for the quarter ended September 30, 2025, of $3,030,000, an increase of $311,000, or 11.4%, from the same period the prior year. Earnings per ...

In a clinical study with 60 people who had an acute migraine during the trial, all participants received an intravenous (IV) infusion of 100 milligrams of ... ginger have also been linked to a rapid ...

Group sales In the first nine months of 2025, Roche achieved sales growth of 7% (2% in CHF) to CHF 45.9 billion due to strong demand for our pharmaceutical and diagnostic products.

But behind the spas’ allure, the evaluation found that clinics nationwide varied widely in their offerings and claims; only 2 ...